{"preliminary_commentary":{"by_channel":{"x_thread":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"LUMMICAR STUDY 2","nct_id":"NCT03915184","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=lummicar-study-2-nct03915184. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Phase 1b will include a dose escalation followed by an expansion cohort to determine the recommended dose for the expansion part. After recommended Phase 2 is determined, patients in Phase 2 will be treated.","label":"CAR-BCMA T Cells","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2034-12-31","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":105,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"zevor-cel","otherNames":["CAR-BCMA T Cell Infusion"],"type":"BIOLOGICAL"}],"last_update":"2023-12-19","lead_sponsor":"CARsgen Therapeutics Co., Ltd.","official_title":"Open Label, Multi-center, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR BCMA T Cells (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2024-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Incidence of Treatment Related adverse events (AEs)","timeFrame":"Day 1 - Month 60"},{"measure":"Identification of Maximum Tolerated Dose (MTD)","timeFrame":"Day 1 - Month 60"},{"measure":"Objective response rate","timeFrame":"Day 1 - Month 60"}],"references":[],"start_date":{"date":"2019-09-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)","url":"https://clinicaltrials.gov/study/NCT03915184"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/lummicar-study-2-nct03915184"}